Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Studies have demonstrated that GLP-1s reduce major adverse cardiovascular events and slow progression of kidney disease, transforming these agents from glucose-lowering drugs into cardiorenal-metabolic disease modifiers with expanded addressable populations [1]
We also look hard at sleep, alcohol, protein intake, and other medications
The PlexusDx Precision Peptide Genetic Test examines key variants in GIPR gene (rs1800437), and metabolic genes like FTO and MC4R that influence your baseline appetite regulation and medication responsiveness
Medicaid coverage for weight loss medications is actively evolving
